Clinical Trials Browser

Phase 2 × Unknown × HER2-negative Breast Cancer × Clear all

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Phase 2 Unknown

HER2-negative Breast Cancer

NCT05263882 2022-03-03

Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

Phase 2 Unknown

HER2-negative Breast Cancer